- Home
- FLX vs CRMD Comparison
FLX vs CRMD Comparison
Compare FLX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- CRMD
- Stock Information
- Founded
- FLX 2013
- CRMD 2006
- Country
- FLX China
- CRMD United States
- Employees
- FLX N/A
- CRMD N/A
- Industry
- FLX
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- FLX
- CRMD Health Care
- Exchange
- FLX NYSE
- CRMD Nasdaq
- Market Cap
- FLX 603.7M
- CRMD 738.4M
- IPO Year
- FLX 2024
- CRMD 2010
- Fundamental
- Price
- FLX $8.18
- CRMD $12.30
- Analyst Decision
- FLX
- CRMD Strong Buy
- Analyst Count
- FLX 0
- CRMD 6
- Target Price
- FLX N/A
- CRMD $15.67
- AVG Volume (30 Days)
- FLX 15.6K
- CRMD 1.4M
- Earning Date
- FLX 02-27-2025
- CRMD 03-11-2025
- Dividend Yield
- FLX N/A
- CRMD N/A
- EPS Growth
- FLX N/A
- CRMD N/A
- EPS
- FLX 0.19
- CRMD N/A
- Revenue
- FLX $663,142,775.00
- CRMD $12,262,234.00
- Revenue This Year
- FLX N/A
- CRMD N/A
- Revenue Next Year
- FLX N/A
- CRMD $246.41
- P/E Ratio
- FLX $44.21
- CRMD N/A
- Revenue Growth
- FLX 1.31
- CRMD 41184.20
- 52 Week Low
- FLX $6.50
- CRMD $2.89
- 52 Week High
- FLX $21.95
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- CRMD 68.48
- Support Level
- FLX N/A
- CRMD $11.74
- Resistance Level
- FLX N/A
- CRMD $13.09
- Average True Range (ATR)
- FLX 0.00
- CRMD 0.72
- MACD
- FLX 0.00
- CRMD 0.37
- Stochastic Oscillator
- FLX 0.00
- CRMD 85.09
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.